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T CELL  GROWTH FACTOR RECEPTORS 
Quant i tat ion,  Specificity, and Biological Relevance* 
By RICHARD J. ROBB, ALLAN MUNCK, AND KENDALL A. SMITH 
From the Immunology Program, Norris Cotton Cancer Center, and the Department of Physiology, Dartmouth 
Medical School, Hanover, New Hampshire 03755 
Recent studies have shown that although antigens and lectins initiate the activation 
of T cells, the proliferation of these cells is dependent on a 15,000-dalton glycoprotein 
designated T cell growth factor (TCGF) 1 (1-9). Accordingly, two antigen-dependent 
events are essential for the realization of a competent T cell proliferative response: the 
production of TCGF (5, 7), and the acquisition of a state of specific responsiveness to 
TCGF on the part of antigen-activated cells (10-13). As a result of this concept it has 
been proposed that there is a unique signaling apparatus within the immune system 
designed to transmit exogenous antigenic stimuli to an endogenous, hormonelike 
control system involving lymphokines (14, 15). 
A number of experimental findings suggest hat TCGF has characteristics similar 
to polypeptide hormones that interact with target cells by means of specific receptors. 
The mitogenic effect of TCGF is strictly concentration dependent such that the rate 
and extent of T cell clonal expansion is determined by the concentration of TCGF 
available (5, 10, 14, 15). Moreover, the effect of TCGF appears pecific for T cells. 
TCGF promotes proliferation only of antigen- or lectin-activated T cells and has no 
mitogenic effect on unstimulated lymphocytes, activated B cells, or cells of other 
lineages (10-15). In addition, TCGF activity is absorbed only by activated T cells 
(10-15). The fact that such absorption is time, temperature, and cell concentration 
dependent, ogether with the finding that both viable and glutaraldehyde-fixed cells 
absorb the activity, has led us (10, 14, 15) and others (11-13) to propose that TCGF 
interacts with activated T cells by means of specific membrane binding sites. 
The definitive demonstration of TCGF-specific binding sites depends upon the 
development of a radiolabeled TCGF binding assay. In this report we describe such 
an assay using highly purified, internally radiolabeled TCGF, and show that only 
TCGF-responsive T cells express high affinity, TCGF-specific binding sites. Moreover, 
the characteristics of the binding, and the close correlation of the binding and 
* Supported in part by grants CA-17643, CA-17323, CA-23108, and CA-26273 from the National 
Cancer Institute; grant CH-167 from the American Cancer Society; and grant AM-03535 from the 
National Institutes of Health. 
1 Abbreviations u ed in this paper: BSA, bovine serum albumin; Con-A, concanavalin A; CSA, colony- 
stimulating activity; CTLL, cytolytic T lymphocyte line; DMEM, modified Dulbecco's e sential medium, 
EGF, epidermal growth factor, FCS, fetal calf serum, FGF, fibroblast growth factor; HTLL, helper T 
lymphocyte line; IEF, isoelectric focusing; IFNa, leukocyte interferon, type 1; IFNT, immune interferon, 
type 2; LAF, lymphocyte-activating factor; LPS, lipopolysaccharide; MSA, multiplication-stimulating 
activity; NGF, nerve growth factor; PHA, phytohemagglutinin; PMA, phorbol myristic acetate; SDS- 
PAGE, sodium dodecyl sulfate-polyacrylamide gel lectrophoresis; TCGF, T cell growth factor; TdR, 
thymidine. 
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biological response curves, support the notion that TCGF,  in a manner similar to 
polypept ide hormones, exerts its effects upon activated T cells through a cellular 
receptor. 
Mater ia l s  and  Methods  
Cell Cultures. Murine TCGF-dependent cytolytic (subclone 15H) (16) and helper (clone 18- 
33-3) (8) T lymphocyte lines were maintained as previously described at population levels 
between 1 × 104 and 5 × 105 cells/ml (doubling time ~20 h) in Iscove's Modified Dulbecco's 
Minimum Essential Medium (Iscove's DMEM; 17) supplemented with 10% heat-inactivated 
(56°C for 30 min) fetal calf serum (FCS, Sterile Systems, Inc., Logan, Utah), 50 U/ml penicillin 
G, 50/~g/ml gentamycin, and 1.0 U/ml human TCGF derived from JURKAT T leukemia 
cells and partially purified by gel filtration (see following sections). All were cultured in a 
humidified atmosphere of 5% CO2 in air at 37°C. 
All human and primate cell lines were maintained in RPMI 1640 medium (Grand Island 
Biological Co., Grand Island, N. Y.) supplemented with 10% FCS, 50 U/ml penicillin G, 50 
/~g/ml gentamycin, and 300/zg/ml fresh L-glutamine at population levels between 2 X 105 and 
1 X 106 cells/ml. 
Human phytohemagglutinin (PHA) blasts were prepared by culturing peripheral blood 
lymphocytes i olated on Ficoll-Hypaque with I p.g/ml PHA (Wellcome Reagents Limited, 
Beckenham, Eng.) in supplemented RPMI 1640 medium for 72 h. Alloantigen-activated 
human blasts were prepared by co-cultivation of peripheral blood mononuclear cells from two 
individuals (1 × 106 cells/ml) in supplemented RPMI 1640 medium for 120 h. Murine 
(BALB/c, The Jackson Laboratory, Bar Harbor, Maine) splenocytes and thymocytes were 
activated with concanavalin A (Con-A, 2.5 pg/ml, Miles Yeda, Rehovath, Israel), Escherichia 
coli lipopolysaccharide (LPS, 20/Lg/ml, Grand Island Biological Co.), and allogeneic splenocytes 
(C57BL/6, The Jackson Laboratory) by culturing cells (2.5 X 106 cells/ml) for 48 h (Con-A, 
LPS) or 120 h (mixed lymphocyte culture) in DMEM (Grand Island Biological Co.) supple- 
mented with 10% FCS, 50 U/ml penicillin G, 50 p.g/ml gentamycin, 2-mercaptoethanol (5 x 
10 -5 M), and 300 #g/ml r-glutamine. When necessary, the proportion of blast cells was enriched 
to 90-95% by discontinuous gradient centrifugation (18). 
TCGF Assay. TCGF biological activity was determined as previously described (5) by the 
TCGF concentration-dependent stimulation of proliferation of a cloned murine cytotoxic T 
lymphocyte line (CTLL-2, subclone 15H) (16). CTLL proliferation, as indicated by [3H]- 
thymidine (TdR) incorporation, was determined during the last 4 h of a 24-h culture period in 
the presence of serial twofold dilutions of a standard TCGF preparation and the experimental 
sample. The dilutions yielding 50% of the maximum CTLL [aH]TdR incorporation were 
determined, and that of the sample divided by that of the standard to give the concentration 
of TCGF in units per milliliter. The standard TCGF preparation, which was arbitrarily 
assigned a value of 1 U/ml, routinely ielded 50% of the maximal incorporation at a dilution 
of 1:I0. Phorbol myristic acetate (PMA) and PHA, which were used to induce TCGF 
production, had negligible direct or synergistic (with TCGF) effects in the assay. 
Production and Purification of lnternally Radiolabeled TCGF. Radiolabeled TCGF was prepared 
by stimulation of a high-producer clone (clone 6) of the human T leukemia cell line JURKAT 
(19, 20), in the presence of a medium containing various radioactive amino acids. Since the 
release of TCGF from JURKAT cells was found to gradually decline with their time in culture, 
fresh aliquots of cells were thawed for each labeling experiment. The cells were grown for 3--5 
d in culture after which they were washed with serum- and methionine-free DMEM (MEM 
Select-Amine Kit, Grand Island Biological Co.). The cells were resuspended at 5 × 106 cells/ml 
in the same medium, to which was added 1.5 p.g/rnl PHA (Wellcome Reagents), 50 ng/ml 
PMA (Consolidated Midland Corp., Brewster, N. Y,), 10 #M unlabeled methionine, and 0.5 
mCi/ml [SSS]methionine (1,100 Ci/mmol, Amersham Corp., Arlington Heights, Ilk). The cell 
supernate was harvested after incubation for 14-18 h at 37°C, after which 1 mg/ml bovine 
serum albumin (BSA, Fraction V, Sigma Chemical Co., St. Louis, Mo.) was added as a carrier. 
Under these conditions ~40 U/ml of TCGF was recovered, representing 40-50% of the optimal 
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production obtained in normal, serum-free DMEM. Exclusion of the unlabeled methionine 
resulted in extremely low levels of secreted TCGF. 
Similar conditions were used for labeling with 3H-amino acids, except hat DMEM contain- 
ing the normal methionine level, 40 p.M unlabeled leucine, 65 #M unlabeled lysine, 0.5 mCi/ 
ml [SH]leucine (55 Ci/mmol, ICN, Irvine, Calif.) and 0.5 mCi/ml [SH]lysine (45 Ci/mmol) was 
substituted. Approximately 50-60% of the optimal release of TCGF was obtained. Lower 
concentrations of total leucine and lysine resulted in a marked decrease in TCGF levels. 
After stimulation of JURKAT cells in the presence of radioactive amino acids, the cell 
supernate (20 ml) was'concentrated 15-fold by uhrafiltration using a YM-5 membrane (Amicon 
Corp., Lexington, Mass.). Concentrated material (>95% recovery of TCGF biological activity) 
was chromatographed at 4°C on a 1.6 × 95-cm column ofSephadex G100 Superfine (Pharmacia 
Fine Chemicals, Piscataway, N. J.) in 10 mM Tris, pH 7.5, 0.15 M NaCI, and 100 #g/ml BSA. 
The yield of TCGF activity was ~76%. The pool of TCGF activity from the G100 column was 
equilibrated on a YM-5 membrane with a 1/160 dilution of Pharmolyte, pH 6.5-9 (Pharmacia 
Fine Chemicals), and further fractionated by isoelectric focusing (IEF). Focusing was performed 
at 4°C on a 6 × 180-mm cylindrical gel (7% acrylamide, 1/16 dilution of Pharmolyte, pH 6.5-9) 
at 1,000 V for 12 h. The gel was cut into 2-mm slices and eluted (72-96 h) in 0.5 ml of 10 mM 
Tris, pH 7.5, 0.15 M NaCI, 2 mg/ml BSA. The biological activity from each slice was measured 
in the TCGF assay and 2.5 #1 was counted by liquid scintillation. A parallel gel (no sample) 
was sliced and eluted with 1 ml distilled water (4°C) for determination f a representative pH 
gradient. Radiolabeled TCGF preparations from the IEF gel were examined by sodium dodecyl 
sulfate-polyacrylamide gel lectrophoresis (SDS-PAGE) on slab gels (12% acrylamide) according 
to the methods of Ziegler et al. (21) and Laemmli (22) with identical results. The gels were 
analyzed by fluorography (23). 
Unlabeled TCGF was similarly prepared by stimulation of JURKAT cells with PHA and 
PMA, and purified in the absence of exogenous protein carriers by a combination of gel 
filtration and IEF (9). Such preparations contained no detectable type 1 or type 2 interferon 
activity (Frank Ruscetti, personal communication), macrophage-granulocyte olony-stimulat- 
ing activity (Frank Ruscetti, personal communication), lymphocyte-activating factor activity, 
B cell growth factor (Benjamin Sredni, personal communication), or PHA (as assessed by direct 
mitogenicity on mouse thymocytes). Unlabeled TCGF was also prepared from rat splenocytes 
by stimulation with Con A as previously described (24). 
Radiolabeled TCGF Binding Assay. All cell types were incubated for 2 h at 37°C in 50 ml 
RPMI 1640, 25 mM HEPES, pH 7.2 and washed three times (50 ml) in order to remove any 
endogenous TCGF. A small increase in the level of detectable receptors was found for the 
TCGF-dependent murine CTLL-2, subclone 15H cells after such treatment. After washing, 
cells were immediately used for binding experiments or were fixed with glutaraldehyde b fore 
binding. Glutaraldehyde fixation was performed by suspending the cells in 2% glutaraldehyde, 
0.14 M NaCI, and 0.05 M cacodylate buffer (pH 7.3) for 15 rain at 3°C, followed by extension 
washing (5 times) to remove glutaraldehyde (14). 
To determine the level of binding, serial dilutions of [aSS]methionine- or [SH]leucine, lysine- 
TCGF were incubated at 37°C with 0.5-2 × 106 cells in a total volume of 200 #1 of RPMI 1640 
supplemented with 25 mM HEPES, pH 7.2, and 10 mg/ml BSA (RPMI 1640-BSA) using 1.5 
ml Eppendorf micro test tubes (2236-411-1, Brinkmann Instruments, Westbury, N.Y.). The 
tubes were mechanically rotated about their longest axis (horizontal position) at 20 rpm in a 
37°C water bath. After 20 or 40 min, 1 ml ice-cold RPMI 1640-BSA was added to each tube 
and the cells were pelleted at 9,000 g for 10 s in an Eppendorf model 5413 centrifuge. The 
supernate was removed and counted by liquid scintillation to determine the level of unbound 
radioactivity. The cells in the pellet were resuspended with 100 #1 RPMI 1640-BSA at 0°C and 
centrifuged at 9,000 g for 90 s through a 200-pl layer of a mixture (25°C) of 84% silicone oil 
(550 fluid, Contour Chemical Co., North Reading, Mass.) and 16% paraffin oil (Fisher Scientific 
Co., Pittsburgh, Pa.) to remove the small amount of unbound TCGF remaining in the original 
pellet. The tips of the tubes (400 #1 polyethylene, Bio-Rad Laboratories, Richmond, Calif.) 
containing the cell pellet were cut-off, placed in scintillation vials, and the pellets olubilized by 
addition of 100/xl 1% SDS followed by 3 ml Biofluor (New England Nuclear, Boston, Mass.). 
The level of nonsaturable binding was determined by adding 25 nM unlabeled JURKAT- 
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derived TCGF (purified by gel filtration or by gel filtration and IEF) to each assay tube before 
addition of the cells. The counting efficiencies for the various [aSS]methionine-TCGF prepara- 
tions and the bound and unbound fractions after cell binding were similar (90-95%) and no 
adjustment was made in the final results. 
The following rowth factors and hormones were examined for competition with the binding 
of radiolabeled TCGF: murine pidermal growth factor (EGF), rat multiplication-stimulating 
activity (MSA), murine 2.5s nerve growth factor (NGF), and bovine fibroblast growth factor 
(FGF), all from Collaborative Research Inc., Waltham, Mass.; murine lymphocyte-activating 
factor (LAF or interleukin 1) prepared by LPS-stimulation ofP388D1 cells (25); purified human 
leukocyte interferon type 1 (IFN-a) (a gift from Dr. Kurt Berg, University of Aarhus, Denmark), 
human immune interferon type 2 (IFN-),) (a gift from Dr. William Stewart, Memorial Sloan- 
Kettering Cancer Center, New York), purified macrophage-granulocyte olony-stimulating 
activity (CSA) (a gift from Dr. Frank Ruscetti, National Cancer Institute, Bethesda, Md.), 
human urinary erythropoietin (2nd international standard), and bovine-porcine insulin (Eli 
Lilly and Company, Indianapolis, Ind.). 
Radiolabeled TCGF: Time-Courses of Association and of Dissociation~Degradation. A time-course of
the association of [aSS]methionine-TCGF with murine CTLL cells (2.5 × 106 cells/ml) was 
determined at 4 ° and 37°C using a saturating level of radiolabeled TCGF (250 pM) in the 
absence and presence of unlabeled TCGF (25 nM). At various times, aliquots (200/tl) were 
removed and centrifuged (9,000 g for 90 s) through a 200-/~1 layer of 84% silicone oil: 16% 
paraffin oil. The tips containing the cell pellet were cut offand the samples treated as described 
for binding assay. 
The dissociation or release of intact or degraded [35S]methionine-TCGF from murine CTLL 
cells was measured intwo ways. In the first approach, a near-saturating level of [35S]methionine- 
TCGF (150 pM) was allowed to bind to the cells for 60 min at 37°C. At that time, the 
concentration of free [aSS]methionine-TCGF was reduced by a 100-fold dilution of the cell 
suspension i to RPMI 1640-BSA and the culture maintained at 37°C. Aliquots of the cell 
suspension (containing 5 × 106 cells) were removed at various time intervals and centrifuged as 
described above through a layer of silicone oil:paraffin oil to separate cell-associated and 
unassociated [aSS]methionine label. In a second approach, a similar level of [aSS]methionine- 
TCGF was allowed to bind to the CTLL cells (2.5 X 106 cells/ml) for 45 min at 4°C. At that 
time, the cells were pelleted and washed once with 1 ml RPMI 1640-BSA at 0°C to remove 
unassociated TCGF. The cells were resuspended at 2.5 × 10 ° cells/ml in RPMI 1640-BSA 
containing 25 nM unlabeled TCGF and incubated at 37°C. At various times aliquots (200 ~1) 
were removed and the cells pelleted as before by centrifugation through silicone oil:paraffin oil. 
An estimate of the proportion of degraded [35S]methionine-TCGF was made by precipitation 
of protein (4 h at 0°C) from aliquots of the complete cell suspension, or of washed cells, by 
adjusting each to a final concentration f 10% TCA (with 1 mg/ml BSA serving as a carrier). 
The supernate (degraded [35S]methionine-TCGF) and precipitate (undegraded [35S]methionine- 
TCGF) were counted separately. 
Biological and Binding Responses. A comparison was made between the percentage of the 
maximum biological response (cell proliferation as measured by [aH]TdR incorporation) and 
the percentage ofsaturable binding of [aSS]methionine-TCGF at various concentrations of free 
TCGF. The level of binding was determined asdescribed for binding assay using murine CTLL 
cells (2.5 × l0 s cells/ml). The level of biological activity was determined asin a standard TCGF 
assay. Murine CTLL cells (2 × 104 c~ls/ml) were incubated at 37°C with quadruplicate s ts 
of twofold dilutions of unlabeled TCGF in DMEM/10% FCS (200 #1 total volume). After 20 
h, the SUlaernate from each dilution were harvested, titered in a TCGF assay, and compared 
with a standard TCGF preparation (1 U/ml) to determine the level of remaining free TCGF. 
The original cells were pulsed with [aH]TdR for 4 h at 37°C, and the level of radioactivity 
incorporated was used as a measure of their biological response to TCGF. 
Results  
Purification of Internally Radiolabeled TCGF. TCGF released by the human T leuke- 
mia cell line JURKAT,  after stimulation with PHA and PMA in the presence of 
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[aSS]methionine, was concentrated and chromatographed on a column of Sephadex 
G100 Superfine (Fig. 1A). TCGF biological activity eluted in a position corresponding 
to a globular protein of 19-20,000 tool wt and was coincident with a small peak of 
[aSS]methionine label. The G100 pool was further fractionated by IEF on a polyacryl- 
amide gel using a gradient of pH 6.5-9. As shown in Fig. 1B, the major peak of 
TCGF activity coincided with a major peak of [~S]methionine label (slices 21-23, pI 
~8.2). A secondary peak of activity (slice 38, pI ~7.9), which represented a sialylated 
form of TCGF (9), also coincided with a peak of [aSS]methionine label. The yield of 
TCGF biological activity in the major IEF peak as compared to the original cell 
supernate was 40%. Quantitatively and qualitatively similar results were obtained for 
fractionation of [aH]leucine, lysine-TCGF. 
When analyzed by one-dimensional SDS-PAGE, followed by fluorography, the 
material from the major IEF peak migrated as a single band of radiolabel at 14,800 
mol wt under nonreducing conditions and 15,500 mol wt under reducing conditions 
(Fig. 2). A single component of the same size was found by slicing a similar gel and 
recovering biological activity (9) and by electrophoresis and conventional staining 
(Coomassie Brilliant Blue R250) of unlabeled JURKAT TCGF purified by the same 
means (Richard Robb, unpublished observations). The similarity between the size 
estimates from gel filtration and SDS-PAGE suggests that a molecule of TCGF is 
composed of a single polypeptide chain. Despite the relative uniformity of the size 
and charge characteristics of [~S]methionine-TCGF from the major IEF peak, 
however, the potential for microheterogeneity requires further examination. 
The level of radioactivity in the major IEF peak depicted in Fig. 1B was 23,600 
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FIc. 1. (A) Elution profile of [aSS]met-radiolabeled c ll supernate derived from PHA and PMA- 
stimulated JURKAT cells on a 1.6 X 95-cm column of Sephadex Gl00 Superfine. A sample (4/d) 
of every second fraction was used to determine the level of TCGF activity and asS radiolabel. 
Standards used to separately calibrate the column were BSA, ovalbumin (OVA), soybean trypsin 
inhibitor (STI), and cytochrome c (CytC). (B) IEF (pH 6.5-9) profile of material from fractions 95- 
100 of the Sephadex G100 column. A sample of each fraction was tested for the presence of TCGF 
(5 p,l) or counted to determine the level of aSS radiolabel (2.5 #l). The pH gradient was determined 
using a parallel gel (no sample). 
1460 T CELL GROWTH FACTOR RECEPTORS 
Fro. 2. SDS-PAGE analysis (with and without 2-mercaptoethanol [2-ME]) of [3~S]methionine- 
TCGF (4,000 cpm) eluted from slices 21-23 of the IEF gel (Fig. 1B). The radioactivity was 
visualized by fluorography. Exposure of the film for a 10-fold longer time did not reveal additional 
bands. The standards used in calibrating the g lwere BSA (66,000), ovalbumin (45,000), trypsinogen 
2(24,000), Mb (I 7,800), lysozyme (14,300), and were stained with Coomassie Brilliant Blue R-250. 
cpm per unit of biological activity. By assaying the protein content of purified 
unlabeled JURKAT TCGF using amino acid analysis and a dye binding assay (26), 
it was determined that a unit of biological activity corresponds to ~8.2 ng of protein 
(Richard Robb, unpublished observations). Therefore, the specific activity of the 
[35S]methionine-TCGF was estimated to be 2,880 cpm/ng or 44,600 cpm/pmol (tool 
wt = 15,500). 
Time-Courses ofAssociation and of Dissociation~Degradation of Radiolabeled TCGF. The 
optimal parameters for cell binding of radiolabeled TCGF were initially determined 
using a cloned murine, TCGF-dependent, T cytolytic line (CTLL-2, subclone 15H). 
Measurement of the time-course of association of [35S]methionine-TCGF with these 
cells at 37°C revealed a very rapid uptake of radiolabel with maximum levels achieved 
within 15 rain (Fig. 3A). The binding was saturable because in the presence of 
unlabeled TCGF (25 nM), very little [35S]methionine-TCGF was associated with the 
cells at any time point. When the incubation was conducted at 4°C instead of 37°C, 
nearly the same maximum level of binding was reached, but only after 60 min of 
culture (Fig. 3A). Similar kinetics of association were found for human PHA blast 
cells. 
Upon a 100-fold dilution of the CTLL cell suspension, most of the ceil-associated 
3~S-radiolabel (present after 1 h binding at 37°C) left the cells within 2 h at 37°C 
(data not shown). Analysis of the released radiolabel, however, revealed that a large 
portion (>70%) was no longer precipitable with 10% TCA in contrast o the nearly 
quantitative precipitation (>97%) of the original preparation of [35S]methionine- 
TCGF. Thus, the radiolabeled TCGF appeared to be undergoing degradation. That 
such degradation might depend upon receptor binding was indicated by the finding 
that unlabeled TCGF (25 nM) added simultaneously with the [~SS]methionine-TCGF 
resulted in an absence of cell-associated radiolabel and a complete lack of degradation. 
Measurement of the rate of conversion of cell-associated [35S]methionine-TCGF 
into a TCA-soluble form at 37°C revealed a half-time of 60-70 min (data not shown). 
A similar value was obtained with [3H]leucine, lysine-TCGF. Since the large number 
of leucines and lysines (230) in JURKAT-derived TCGF (Richard Robb, unpub- 
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Fxc;. 3. (A) Time-course of the association of [35S]methionine-TCGF with CTLL-2, subclone 15H 
cells in the absence (0, 37°C; m, 4°C) and presence (C), 37°C) of 25 nM unlabeled TCGF. These 
and subsequent values for the number of TCGF binding sites per cell are based on the estimated 
specific activity of 44,600 cpm/pmol [~S]methionine-TCGF. As an example, a level of 14,000 
molecules per cell represents he binding of 520 cpm of [~S]methionine-TCGF per 5 × 105 CTLL 
cells. (B) Time-course of the release (Q) at 37°C of [35S]radiolabel from CTLL cells following 45 
min binding at 4°C, removal of unassociated radiolabel, and addition of 25 nM unlabeled TCGF 
to promote xchange. Aliquots of the whole cell suspension were removed at various times and 
adjusted to 10% TCA to determine the level of precipitable 35S radiolabel (A). 
lished observations) are likely to be distr ibuted throughout he molecule, the conver- 
sion of the 3H radiolabel to a TCA-soluble form implies general degradat ion of the 
molecule rather than removal of a small, methionine-r ich section. In contrast o these 
results at 37°C, at 4°C virtual ly all of the radiolabel remained TCA precipitable for 
>2 h. Furthermore,  inclusion of either ammonium chloride (10 mM) or chloroquine 
(100 #M), which have been shown to inhibit lysosome-dependent hormone degrada- 
tion (27-32), resulted in >90% inhibit ion of the converstion of  [3~S]methionine-TCGF 
to a TCA-soluble form at 37°C, while having no effect on the level of binding. Thus, 
degradat ion of  TCGF is temperature dependent and appears to involve internal izat ion 
and lysosomal association. 
When binding was carried out for 45 min at 4°C to block degradation,  followed by 
warming to 37°C and addit ion of 25 nM unlabeled TCGF to promote exchange, 
about half  the cell-associated label was released within 45 rain (Fig. 3B). Under  these 
condit ions within only about one-third of the [3SS]methionine-TCGF degraded, 
presumably because dissociation of labeled TCGF occurred faster than degradation. 
Thus, association of TCGF with CTLL  cells is largely reversible and is characterized 
by rapid binding, slow dissociation (tl/z at 37°C of 40-50 min), and receptor- and 
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lysosome-dependent degradation of the molecule. Despite the degradation, the level 
of [35S]methionine-TCGF associated with the cells (surface-bound and/or internalized, 
intact and/or degraded) remained stable for at least 60 rain at 37°C (Fig. 3A). 
Subsequent measurements of binding capacity and receptor affinity were made after 
20 or 40 rain of culture at 37°C with little difference in the results. 
Radiolabeled TCGF Binding: Cell Type, Number of Receptors, and Affinity. Incubation of 
increasing concentrations of [Z~S]methionine-TCGF with antigen-specific, TCGF- 
dependent murine CTLL-2 (subclone 15H) and HTLL (clone 18-33-3) cell lines 
demonstrated that the binding consisted predominantly of a saturable component 
(Fig. 4A). Nonsaturable binding was estimated by including 25 nM unlabeled TCGF 
during the incubation. The level of binding that remained was linearly dependent 
upon the concentration of free [3~S]methionine-TCGF and generally constituted <4% 
of the total bound fraction in the absence of unlabeled TCGF. The average number 
of receptor sites per cell was ~ 15,000 for the CTLL and 13,000 for the HTLL (Table 
I). The sialylated form of [35S]methionine-JURKAT TCGF (IEF slice 38, Fig. 1B) 
and the major IEF peak of [3H]leueine, lysine-JURKAT TCGF gave similar estimates 
of the number of receptor sites for the CTLL line. In addition, glutaraldehyde-fixed 
CTLL cells bound almost as much [35S]methionine-TCGF as viable cells (Table I). 
Binding of [3~S]methionine-TCGF to murine splenocytes and thymocytes (BALB/ 
c) indicated fewer than the minimum detectable vel of 60 binding sites per cell (Fig. 
4A, Table I). Upon stimulation with Con A or by alloantigen, however, a significant 
level of binding sites was found on both splenocyte and thymocyte blasts (Fig. 4A, 
Table I). In contrast, splenocytes stimulated with lipopolysaccharide w re found to 
have no detectable receptors. These results are consistent with those of previous 
experiments in which only activated T cells, but not unstimulated lymphocytes or B 
cells blasts, absorbed TCGF biological activity (10-15). The fact that antigen-acti- 
vated and lectin-activated cells both have binding sites with similar affinities for 
TCGF indicates that the activation step is the critical event in acquisition of TCGF 
responsiveness and that the lectin is not directly involved in the binding. 
A Scatchard plot of the binding of [ZSS]methionine-TCGF to the murine CTLL 
and HTLL  cell lines and Con A-activated splenocytes indicated a linear relationship 
(Fig. 4B) and a similar apparent dissociation constant (Table I) in each case. These 
results imply that a single set of high-affinity binding sites is responsible for the 
saturable binding. 
A similar analysis of binding to unstimulated human peripheral blood cells (90% 
lymphocytes) demonstrated an average of 200 binding sites per cell (Table I). Upon 
activation of the cells for 3 d with PHA or in a mixed lymphocyte reaction, the level 
of binding sites increased markedly to ~ 11,000 and 4,000 per cell, respectively (Fig. 
5A, Table I). As with the murine cells, a linear relationship was obtained on the 
Scatchard plot (Fig. 5B). The apparent affinity of the human cell-surface receptor, 
however, was three to fourfold higher than that of the murine receptor (Table I). 
A number of established human cell lines (including 10 T cell lines, 4 B cell lines, 
2 myeioid cell lines, and a monocytoid cell line), which previous tudies had shown to 
be unresponsive toTCGF (33), were found to have fewer than the detectable number 
of binding sites for [3~S]methionine-TCGF (Table II). In contrast, two T cell lines 
(HUT-102B2 and MLA-144) known to produce and respond to TCGF 2 (34, 35), 
2 Smith, K. A., R. J. Robb, and F. W. Ruscetti. The effect of glucocorticoids on T cell growth factor- 
dependent leukemic ell growth. Manuscript submitted for publication. 
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expressed binding sites that had apparent affinity constants similar to that of human 
PHA blast cells (Fig. 5, Table II). 
Competition for Radiolabeled TCGF Binding. The specificity of radiolabeled TCGF 
binding for murine CTLL cells and human PHA blast cells was examined by 
introducing a variety of growth factors and hormones as potential competitors for the 
binding. In cases where physiological concentrations were known (i.e., EGF, NGF, 
insulin, interferon, erythropoietin, LAF), the factors were used at levels above those 
known to illicit a maximum response. As shown in Table III, none of the growth 
factors tested had any measurable effect on the binding of [3~S]methionine-TCGF to 
murine CTLL cells. Of special note is the finding that LAF, which provides a 
necessary signal for TCGF release by T cells (36-38), did not compete for [35S]- 
methionine-TCGF binding. Moreover, human interferon, macrophage-granulocyte 
CSA, insulin, and erythropoietin also failed to exert a significant effect on [aSS]- 
methionine-TCGF binding to human PHA blast cells. 
Competition for [35S]methionine-TCGF binding was also examined using different 
preparations of TCGF. As shown in Table III, unlabeled TCGF derived from 
JURKAT cells (purified through IEF and/or gel filtration) almost completely abro- 
gated [35S]methionine-TCGF binding to both murine CTLL cells and human PHA 
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TABLE I 
Characteristics of [asS] Methionine-TCGF Binding to Unstimulated and Stimulated Ceils 
Cell type Stimulant [a'~S]Methionine-TCGF binding* 
Sites~cell Dissociation 
constant 
(X 10 -'2 M) 
Murine cells 
Splenocytes - <60 - 
Thymocytes - <60 - 
Splenocytes Con A 9,000 ± 340 19.6 + 1.1 
Splenocytes Alloantigen 5,800 + 400 24.6 _-. 4.1 
Thymocytes Con A 3,180 ± 310 19.1 ± 1.5 
Splenocytes LPS <60 - 
CTI,L-2, subclone 15H -- 14,800 ± 1,900 20.4 ± 0.8 
CTLL-2, subclone 15H - 13,200 - 
(glutaraldehyde-fixed) 
HTLL, clone 18-33-3 - 12,700 ± 2,300 20.1 ± 1.6 
Human cells 
Peripheral blood mononuclear cells - 210 7.4 
Peripheral blood mononuclear cells PHA 10,900 ± 240 5.4 + 1.1 
Peripheral blood mononuclear cells Alloantigen 4,300 ± 340 4.9 + 0.4 
* The calculated values of the number of binding sites per cell and the dissociation constant are based on 
35, i the estimated specific activity of 44,600 cpm/pmol [ S]meth onine-TCGF and represent the mean and 
SEM of two or more determinations. 
blast cells. Although JURKAT-der ived  TCGF migrates as a single major peak on 
IEF (pI 8.2), TCGF derived from normal human tonsil cells is heterogeneous with 
respect to charge, separating into three distinct forms (pI 8.2, 7.9, and 7.6) (9). 
Previous studies revealed that this heterogeneity is due to variable sialylation and 
glycosylation, and that the carbohydrate component is not essential for biological 
activity (9). It was of interest, therefore, to determine the relative competit ive efficiency 
of each of the three species of tonsil-derived TCGF isolated from IEF gels in the 
[a~S]methionine-TCGF binding assay. When present at 2 nM TCGF,  each of the three 
IEF fractions was capable of almost completely inhibit ing [3~S]methionine-JURKAT 
TCGF binding to CTLL  cells (Table III). Furthermore, when compared on the basis 
of biological activity (TCGF cell-proliferation assay), very similar concentrations of
unlabeled JURKAT TCGF and of the three tonsil-derived IEF fractions were needed 
to reduce the binding of [35S]methionine-TCGF by 50% (data not shown). The finding 
that tonsil-derived material  of three distinct isoelectric points competed for 
[3~S]methionine-TCGF binding relative to its respective TCGF biological activity 
supports the impression that the substance responsible for the competit ion, as well as 
the binding, is TCGF,  and not a contaminant  in the JURKAT-der ived  preparations 
(both radiolabeled and unlabeled). 
The concentration dependence of the competit ion of unlabeled TCGF with [3~S]- 
meth ion ine-TCGF binding is shown in Fig. 6. Unlabeled JURKAT-der ived  TCGF 
competed for [35S]methionine-TCGF binding to both murine CTLL  cells and human 
PHA blast cells with nearly superimposable curves. The concentration of unlabeled 
TCGF leading to 50% competit ion was 0.068 U/0.2 ml, nearly the same as the 
concentration of [aSS]methionine-TCGF (0.066 U/0.2 ml) used in the reaction mixture. 
Since at this level of radiolabeled TCGF (175 pM) the binding was at saturation 
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(Figs. 4A and 5A), addition of an equal amount of unlabeled TCGF would be 
expected to give ~50% competition. 
In comparison to unlabeled human TCGF, TCGF derived from Con A-activated 
rat splenocytes was approximately six-fold less effective in competing with [35S]- 
methionine-TCGF for binding to murine CTLL cells (50% competition occurred at 
0.4 U/0.2 ml) (Fig. 6). This result could mean that human TCGF has a higher affinity 
for the murine cell binding site than does rag TCGF. Of particular note with regard 
to the correlation of [~S]methionine-TCGF binding and biological activity was the 
finding that although rat TCGF competed for [3SS]methionine-TCGF binding to 
murine cells, there was no competition by rat TCGF for binding to human PHA blast 
cells (Fig. 6). This result corresponds to our prior findings on the species restriction of 
TCGF; i.e., that rat TCGF has mitogenic activity for murine cells but not for human 
cells (5). 
Comparison of TCGF Biological Activity and Radiolabeled TCGF Binding. In assessing 
the biological relevan~ze of the binding demonstrated for radiolabeled TCGF, it was 
of particular interest o compare the concentrations of TCGF that result in significant 
binding with those responsible for in vitro proliferation. Seria~l two-fold dilutions of 
unlabeled JURKAT TCGF were incubated with the murine CTLL line as in a 
standard TCGF assay. After 20 h of culture, the supernates were harvested and placed 
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TABLE II 
Characteristics of [asS]Methionine-TCGF Binding of Cell Lines 
Cell line Cell type 
[35S]Methionine-TCGF binding* 
Dissociation con- Sites/cell stant (× 10 -12 M) 
CCRF-CEM T <60 - 
HPB-MLT T <60 - 
HSB-2 T <60 - 
JM T <60 - 
JURKAT (clone 6) T <60 - 
MOLT-3 T <60 - 
MOLT-4 T <60 - 
PEER T <60 - 
RPMI 8402 T <60 - 
T-ALL- 1 T <60 - 
HUT-102B2 T 13,000 + 1,900 6.0 • 0.6 
DAUDI B <60 
RM- 1 B <60 
RPMI 1788 B <60 
RAJI B <60 
K-562 Myeloid <60 - 
HL-60 Promyelocyte <60 - 
U-937 Monocytoid <60 - 
MLA-144 (clone 15) Primate T cell 8,200 :t: 2,100 8.0 :t: 0.2 
* Values represent the mean and SEM of two or more determinations. 
into a second TCGF assay to measure the concentration of TCGF remaining after 
exposure to the cells. The cells from which the supernates were taken were then pulsed 
with [3H]TdR to measure their response to the original exposure to TCGF. When the 
data resulting from the [3H]TdR incorporation of the original cells were compared to 
the concentration f free TCGF remaining after the incubation, it was clear that, over 
a wide range, the rate of CTLL  [aH]TdR incorporation was logarithmically related 
to the concentration of free TCGF. When the data from this experiment were 
compared to the binding curve for [3~S]methionine-TCGF to CTLL  cells (Fig. 7), the 
concentration of TCGF that stimulated a given fraction of the maximum CTLL 
proliferation was remarkably similar to" the concentration that resulted in the same 
fraction of occupied receptor sites. For example, the concentration of TCGF that 
promoted half-maximal [aH]TdR incorporation was 0.03 U /ml  (16 pM) and the 
concentration of [aSS]methionine-TCGF giving half-maximal b inding was 0.04 U /ml  
(21 pM). Moreover, the maximum biological response occurred at a concentration of 
TCGF that corresponded to ~90% saturation of the binding sites. The similarity 
between the biological dose-response curve and the [3~S]methionine-TCGF binding 
curve indicates that the biological response is nearly proportional to the TCGF-  
binding site occupancy. 
Discussion 
The restriction of radiolabeled TCGF binding to TCGF-responsive cells, the lack 
of competition by other growth factors and hormones, the high affinity of the binding, 
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TABLE III 
Competition for [asS]Methionine- TCGF Binding* 
1467 
Potential competitors Concentration 
Target cells 
Murine CTLL cells Human PHA blast cells 
sites~cell 
Control - 14,000 ± 340 
EGF 2 #M 14,000 ± 1,100 
NGF (2.5 s) 0.5 #M 14,100 ± 340 
MSA 1 ~tM 14,000 ± 200 
FGF 1 #M 13,600 ± 60 
LAF 60 U/ml 14,000 ±340 
IFN-a 40,000 U/ml 
IFN-y 40,000 U/ml 
CSA 
Erythropoietin 5 U/ml 
Insulin (bovine-porcine) 10 U/ml 
TCGF (JURKAT) 2 nM 150 ± 80 
TCGF (tonsil, IEF pI 8.2) 2 nM 110 ± 30 
TCGF (tonsil, IEF pI 7.9) 2 nM 140 + 20 
TCGF (tonsil, IEF pI 7.6) 2 nM 180 ± 70 
% inhibi- 
lion 
0 
0 
0 
0 
3 
0 
99 
99 
99 
99 
sites~cell % inhibi- 
lio?l 
10,300 ± 340 0 
10,000 + 760 3 
10,800 ± 60 0 
10,100 ± 410 2 
10,400 ± 680 0 
10,200 ± 800 1 
80 ± 20 99 
* The assays were performed with [3SS]methionine-TCGF at a near-saturating concentration (~120 pM 
free TCGF for the murine CTLL and 75 pM free TCGF for the human PHA blasts). Values represent 
the mean and SEM of two determinations. 
and the close correlation between the concentrations of TCGF that bind to ceils and 
those that mediate the T cell proliferative response, all support the conclusion that 
the binding site detected in these studies is on the receptor through which the 
biological effects of TCGF are initiated. The implication of these findings is that, for 
the first time, it will be possible to apply a quantitat ive approach to physiological nd 
pathophysiological studies of an immunological ly important lymphokine and its 
receptor. 
The lack of detectable TCGF binding sites on unst imulated murine lymphocytes, 
as well the presence of very few binding sites on unst imulated human peripheral 
blood lymphocytes, stands in contrast to the easily detectable levels found on 
alloantigen- and lectin-activated murine and human cells. These results provide an 
explanation for the observation that highly purified, lectin-free TCGF does not 
promote detectable mitosis of unst imulated lymphocytes, whereas TCGF initiates and 
maintains the proliferation of T cells once activated by antigen or lectin (10-15). The 
low level of b inding sites found on unstimulated human peripheral blood lymphocytes 
(200 sites/cell) is just above the detection limit of the assay and represents only 30 
cpm bound/2  × 106 cells. Since the assay yields only an average level of b inding in 
the whole cell population, the value of 200 sites/cell could represent a low level of 
receptor sites on most or all of the cells, or a high level of sites on a small fraction 
(<2%) of activated cells within the population. If this latter possibility were true, then 
the determination of the level of TCGF receptor sites in various disease states could 
yield information as to the proportion of circulating, activated T cells. 
The increase in the level of receptor sites found upon alloantigen and lectin 
stimulation (>50-200-fold) mirrors earlier studies by ourselves and others where 
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absorption of biological activity was found to be restricted to activated cells (10-13). 
The magnitude of the rise in receptor number after activation cannot be solely 
attributed to an increase in cell surface area as a result of blastogenesis (based on cell 
volume determinations, the surface area increased only 4-8-fold). Rather, the data 
support an actual increase in the average surface density of receptor sites. In addition, 
the lack of detectable [~SS]methionine-TCGF binding to LPS-activated B cell blasts, 
which were the same size as the lectin-activated blasts, not only lends support o this 
conclusion but also confirms that the high affinity of TCGF for activated lymphocytes 
is restricted to T cell blasts. 
In addition to lectin- and antigen-activated cells, cloned, antigen-specific cytolytic 
and helper TCGF-dependent murine T cell lines also expressed significant numbers 
of receptor sites. In contrast o most human T cells cultured in TCGF-containing 
medium, which often require periodic restimulation with antigen to maintain respon- 
siveness to TCGF (39), these murine lines have retained their sensitivity to TCGF, 
without restimulation, for several years in culture (3, 8). Moreover, the number of 
receptor sites detected on these cells has fluctuated <20% over a 6-too period. Together 
with the data on antigen- and lectin-activated cells, these findings emphasize that the 
appearance and persistence ofTCGF-speciflc binding sites are critical parameters for 
T cell clonal expansion. 
The lack of receptor sites on all of the non-T cell, and most of the neoplastic T cell 
lines thus far examined, isconsistent with their apparent lack of TCGF responsiveness. 
Presumably, these cell lines are either fixed in an autonomous proliferative cycle or 
respond to an as yet unidentified endogenous "growth" factor. The human HUT- 
I02B2 and gibbon ape MLA-144 cell lines, however, did manifest an appreciable 
number of receptor sites that bound [3SS]methionine-TCGF with an affinity similar 
to that found for activated human T cell blasts. In recent studies, these two cell lines 
have been shown to be unique, since they appear to both produce and respond to 
TCGF. Although the HUT-102B2 cells release barely detectable levels of TCGF 
activity into the culture medium, TCGF-Iike activity is easily demonstrable on the 
cell surface as shown by acid-glycine lution (35). Furthermore, HUT-102B2 cells are 
responsive to TCGF, since unlike other cell lines tested, exogenous supplementation 
with TCGF enhances their growth rates (35). The MLA-144 cell line is somewhat 
different in that TCGF activity is easily detectable in the culture medium (34). That 
MLA-144 cells are TCGF-responsive was recently shown through studies employing 
glucocorticoids. 2 As has been shown for normal T cells (40, 41), glueocorticoids inhibit 
TCGF production by MLA-144 cells and also suppress their rate of proliferation. 
TCGF supplementation counteracts his effect in a concentration-dependent fashion. 
The restriction of the binding of radiolabeled TCGF to T cell blasts and TCGF- 
dependent T cell lines, together with the finding that TCGF selects only for T cell 
growth (10-15), suggests that TCGF does not directly interact with B cells. Although 
TCGF was the prototype lymphokine for the class of biologically active molecules 
designated interleukin 2, subsequent observations ofB cell proliferation or maturation 
that have been attributed to this class of molecules (42, 43) should be interpreted with 
caution. Such B cell responses could well be due to the effect of TCGF on residual T 
cells in the T-depleted cell populations used in the experiments or to components of 
the interleukin 2 preparations other than TCGF. In this regard, the purification of 
TCGF from JURKAT leukemia cells may have been aided due to the fact that these 
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cells, in contrast to a heterogenous normal mononuclear cell population, do not 
produce detectable quantities of several other biologically active moieties (e.g., CSA, 
B cell-stimulating factor(s), LAF) upon lectin stimulation. 
The absolute values for the dissociation constant and number of binding sites per 
cell are dependent upon preliminary estimates of the purity and the specific activity 
of the radiolabeled TCGF preparations. While the JURKAT-derived [35S]methionine- 
TCGF was reasonably uniform with respect o pI and to size on SDS-PAGE, a 
definitive demonstration f homogeneity requires further examination. In this regard, 
however, since material from each of the three distinct IEF peaks of tonsilar TCGF 
competed almost equally with JURKAT-derived [35S]methionine-TCGF binding, it 
seems highly unlikely that a significant portion of the bound radiolabel could represent 
a copurifying contaminant. In addition, at the lowest concentrations of [3~S]methio- 
nine-TCGF tested on human PHA blasts, as much as 80-85% of the total radiolabel 
was in the bound fraction, suggesting that this is a minimum estimate of the 
proportion of TCGF in the preparation. The specific activity used in the calculations 
was based on a preliminary estimate of the relationship between biological activity 
and protein mass. The latter value is dependent on the purity of the unlabeled TCGF 
preparations and the accuracy of the biological and protein assays. Any error would 
result in a systematic shift in the receptor number and dissociation constant. Never- 
theless, while the absolute values presented in this report may be somewhat in error, 
the relative abundance and apparent affinities of the receptor sites on the different 
types of stimulated and unstimulated cells, and the conclusions based on those relative 
values are unlikely to be affected. 
The seeming linearity of the data when analyzed by Scatchard plots is consistent 
with all of the receptor sites on a given cell type having approximately the same 
affinity for TCGF. The dissociation constant is only an apparent one, however, since 
processes of internalization and/or degradation may be taking place during the time 
used to measure binding. If significant amounts of degraded [35S]methionine TCGF 
were released from the cell, then the value of free TCGF assumed to correspond to 
equilibrium conditions would have been overestimated. Nevertheless, the data indi- 
cate, within experimental error, that receptor sites on murine Con-A and alloantigen- 
activated blasts and long-term T helper and cytolytic ell lines all have roughly the 
same apparent affinity. Similarly, the receptor sites on human PHA and alloantigen- 
activated blasts and HUT-102B2 cells also appear to have approximately the same 
affinity. The affinity of the receptor sites of the human and gibbon ape cells (MLA- 
144), however, were significantly higher than those of murine cells for human TCGF. 
The binding of radiolabeled TCGF to murine and human cells was similar in many 
respects to the binding of other polypeptide hormones and factors to their target cells. 
Like insulin (44) and EGF (29), the binding was rapid and largely reversible. 
Moreover, the binding sites appeared to be on the cell surface because glutaraldehyde- 
fixed cells bound nearly as much [3~S]methionine-TCGF as viable cells and the 
majority of TCGF biological activity could be eluted after absorption to such fixed 
cells (14). As in the case of several other polypeptide factors (28-32), radiolabeled 
TCGF underwent degradation that was time, temperature, and receptor dependent. 
In addition, as with insulin (32), EGF (28, 29), and human growth hormone (30, 31), 
degradation was blocked by the lysosomotropic agents, ammonium chloride and 
chloroquine. By analogy to these and other polypeptide factors (45), the cellular 
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degradation of TCGF can be expected to involve internalization by adsorptive 
pinocytosis and lysosomal association. 
Besides erving as a means of detecting cellular eceptors, the binding assay can be 
used as in Fig. 6 as a competitive assay for unlabeled TCGF. Compared with the 
biological assay of proliferation, the competitive assay is faster (1 vs. 24 h for murine 
CTLL or 48 h for human target cells) and should avoid some of the complications of 
nonspecific inhibitors of cell division and metabolism that affect the proliferation 
assay. Moreover, increasing the specific activity of the radiolabeled TCGF by increas- 
ing the ratio of labeled to unlabeled amino acids in the original culture or by 
improving the efficiency of their incorporation, should enhance the sensitivity of the 
competitive assay (about 0.3 U TCGF/ml) by allowing the use of a lower molar 
concentration of radiolabeled TCGF. In this regard, attempts to prepare high specific 
activity, radioiodinated TCGF have thus far met with disappointing results (Dr. 
Richard Robb, unpublished observations). A significant portion of the TCGF biolog- 
ical activity was consistently lost during the labeling process, a fact which would 
complicate valuation of the subsequent binding data. Internally radiolabeled TCGF 
has an advantage in that the radiolabeled molecules behave identically with unlabeled 
molecules in associating with the celluar receptor (as determined by substituting 
various amounts of unlabeled TCGF for [35S]methionine-TCGF during the binding 
assay). In addition, the ~S-, and especially the 3H-, substituted molecules have a 
much longer half-life than iodinated preparations. 
The biological relevance of the TCGF receptor sites described in this report is 
emphasized by the close correlation between the concentrations of TCGF giving rise 
to a proliferative response (16 pM free TCGF mediated half-maximal proliferation of 
TCGF-dependent CTLL cells) and the concentrations leading to significant occupa- 
tion of receptor sites (21 pM free [~SS]methionine-TCGF ledto half-maximal binding). 
This finding provides an explanation for the strict TCGF concentration-dependence 
of T cell proliferation that serves as the quantitative basis for the biological TCGF 
assay. Moreover, because TCGF appears to be degraded once TCGF-receptor binding 
occurs, it necessarily follows that the dynamics of TCGF-receptor turnover in part 
determines the concentration of TCGF available to proliferating T cells. As a result 
of these findings, it may be anticipated that the extent of in vitro, and most probably 
in vivo, T cell clonal expansion after lectin or antigen activation is determined by the 
TCGF concentration, the acquisition and persistence of TCGF-specific receptors, the 
affinity of the receptors for TCGF, and the rate of degradation of TCGF and its 
receptor. It appears, therefore, that an endocrinological pproach to the study of 
TCGF and its receptor will provide not only new insight important for the in vitro 
cultivation of T cells, but possibly new diagnostic and therapeutic approaches for 
dealing with disorders that involve T cells. 
Summary  
To examine directly the hypothesis that T cell growth factor (TCGF) interacts with 
target cells in a fashion similar to polypeptide hormones, the binding of radiolabeled 
TCGF to various cell populations was investigated. The results indicate that TCGF 
interacts with activated T cells via a receptor through which it initiates the T cell 
proliferative response. 
Internally radiolabeled TCGF, prepared from a human T leukemia cell line and 
1472 T CELL GROWTH FACTOR RECEPTORS 
purified by gel filtration and isoelectric focusing, retained biological activity and was 
uniform with respect to size and charge. Binding of radiolabeled TCGF to TCGF-  
dependent cytolytic T cells occurred rapidly (within 15 rain at 37°C) and was both 
saturable and largely reversible. In addition, at 37°C, a receptor- and lysosome- 
dependent degradation of TCGF occurred. Radiolabeled TCGF binding was specific 
for activated, TCGF-responsive T cells. Whereas unstimulated lymphocytes of human 
or murine origin and lipopolysaccharide-activated B cell blasts expressed few if any 
detectable binding sites, lectin- or alloantigen-activated cells had easily detectable 
binding sites. Moreover, compared with lectin- or alloantigen-activated T cells, long- 
term TCGF-dependent cytolytic and helper T cell lines and TCGF-dependent neo- 
plastic T cell lines bound TCGF with a similar affinity (dissociation constant of 5-25 
pM) and expressed a similar number of receptor sites per cell (5,000-15,000). In 
contrast, a number of TCGF-independent cell lines of T cell, B cell, or myeloid origin 
did not bind detectable quantities of radiolabeled TCGF. Binding of radiolabeled 
TCGF to TCGF-responsive cells was specific, in that among several growth factors 
and polypeptide hormones tested, only TCGF competed for binding. Finally, the 
relative magnitude of T cell proliferation induced by a given concentration of TCGF 
closely paralleled the fraction of occupied receptor sites. As the extent of T cell clonal 
expansion depends on TCGF and on the TCGF receptor, the dissection of the 
molecular events surrounding the interaction of TCGF and its receptor that these 
studies permit, should provide new insight into the hormonelike regulation of the 
immune response by this lymphokine. 
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